September 2015, Vol. 2, No. 5
Enthusiasm Mounts as Immunotherapy Continues to Play a Positive Role in Many Disease StatesLetter to Our Readers
I am writing to you with a renewed enthusiasm for the field of immunotherapy in oncology after hosting the World Cutaneous Malignancies Congress this summer! This educational opportunity is an event of which I am proud, as world-renowned experts convene to present the most up-to-date information on the treatment of cutaneous malignancies. It is our great pleasure to bring this information to you in hope of enhancing your ability to provide the best care possible to your patients. In these pages you will read about the molecular biology of cutaneous malignancies as well as emerging approaches to treating advanced melanoma, basal cell carcinoma, cutaneous T-cell lymphoma, and Merkel cell carcinoma.
You will read continuing coverage from other meetings as well, where immunotherapy continues to make headlines and impact our understanding of how best to care for our patients.
We continue our series of immunotherapy in specific disease states. In this issue, you will find our in-depth report on immunotherapy in breast cancer to include a discussion of vaccines, checkpoint inhibitors, T-cell therapy, and antibodies.
Addressing the business aspect of the immunotherapy field, we are pleased to offer an editorial by Rachel Laign, PhD, and Olivier Lesueur of Bionest Partners on the timeli- ness of partnerships between developers of targeted therapies and immunotherapies and the potential clinical impact.
Please enjoy this issue; I hope your enthusiasm for the art of medicine continues to grow.
Sanjiv S. Agarwala, MD
Editor in Chief
Immunotherapy in Oncology
Although acute lymphoblastic leukemia (ALL) is predominantly a disease found in children, the incidence peaks again in older adults, who have a high risk of treatment-related mortality. Thus, effective and better tolerated treatment of ALL in older patients is an unmet clinical need, said David I. Marks, MD, PhD, University [ Read More ]
Advanced urothelial bladder cancer (UBC) joins the list of tumor types for which treatment with pembrolizumab, a programmed death-1 (PD-1) inhibitor with dual blockade of its ligands PD-L1 and PD-L2, holds promise. Updated safety and efficacy data from the phase 1b KEYNOTE 012 study showed an overall response rate (ORR) [ Read More ]